

## FITC anti-mouse CD69 Antibody

<b>Catalog# / Size</b>	104505 / 50 µg 104506 / 500 µg
<b>Clone</b>	H1.2F3
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
<b>Isotype</b>	Armenian Hamster IgG
<b>Description</b>	CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

### Product Details

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Armenian Hamster
<b>Immunogen</b>	Mouse dendritic epidermal T cell line Y245
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
<b>Concentration</b>	0.5 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm)
<b>Application Notes</b>	The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: <i>in vitro</i> T cell and NK cell activation <sup>1-3</sup> , immunohistochemistry <sup>4,5</sup> , and immunoprecipitation <sup>1</sup> .  This antibody has been characterized in the literature as containing a lambda (?) light chain.

### Application References

(PubMed link indicates BioLegend citation)

1. Yokoyama WM, *et al.* 1988. *J. Immunol.* 141:369. (IP)
2. Sobel ES, *et al.* 1993. *J. Immunol.* 150:673.
3. Karlhofer FM, *et al.* 1991. *J. Immunol.* 146:3662.
4. Zhou X, *et al.* 2005. *J. Biol. Chem.* 280:31240. (IHC)
5. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC)
6. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
7. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181.
8. Epardaud M, *et al.* 2008. *Cancer Res.* 15:2972. [PubMed](#)
9. Jordan JM, *et al.* 2008. 76:3717. [PubMed](#)
10. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
11. Ishikawa C, *et al.* 2013. *Biochim Biophys Acta.* 167:99. [PubMed](#)

## Product Citations

1. Sun L, *et al.* 2021. Cancer Cell. :. [PubMed](#)
2. Zheng X, *et al.* 2019. PLoS Pathog. 15:e1008036. [PubMed](#)
3. Cordero-Reyes A, *et al.* 2016. J Am Heart Assoc. 5: 002484. [PubMed](#)
4. Song Y, *et al.* 2020. Front Immunol. 11:558143. [PubMed](#)
5. van Vloten JP, *et al.* 2022. J Immunother Cancer. 10:.. [PubMed](#)
6. Buxadé M, *et al.* 2018. J Exp Med. 215:2901. [PubMed](#)
7. Farsakoglu Y *et al.* 2019. Cell reports. 26(9):2307-2315 . [PubMed](#)
8. Kim CJ, *et al.* 2018. Immunity. 49:1034. [PubMed](#)
9. Duan Q, *et al.* 2021. Front Cell Dev Biol. 9:761193. [PubMed](#)
10. de Mingo Pulido , *et al.* 2021. Immunity. 54(6):1154-1167.e7. [PubMed](#)
11. Byun JK, *et al.* 2020. Molecular Cell. 80(4):592-606.e8. [PubMed](#)
12. Burrack AL, *et al.* 2019. Cell Rep. 28:2140. [PubMed](#)
13. Chen J *et al.* 2018. Cell reports. 25(12):3393-3404 . [PubMed](#)
14. Álvaro de Mingo Pulido *et al.* 2018. Cancer cell. 33(1):60-74 . [PubMed](#)
15. Castellanos CA, *et al.* 2021. Sci Immunol. 6:eabh0707. [PubMed](#)
16. Liu Q, *et al.* 2021. Cell Death Dis. 12:240. [PubMed](#)
17. Bartleson JM, *et al.* 2020. Nat Immunol. 1384:21. [PubMed](#)
18. Luff DH, *et al.* 2021. Front Immunol. 631271:12. [PubMed](#)
19. Demircioglu F, *et al.* 2020. Nat Commun. 11:1290. [PubMed](#)
20. Hasezaki T, *et al.* 2020. Sci Rep. 10:6969. [PubMed](#)
21. Mitchell JE, *et al.* 2021. Cell Reports. 35(2):108966. [PubMed](#)
22. Uchimura T *et al.* 2018. Immunity. 49(6):1049-1061 . [PubMed](#)
23. Bhattacharjee P, *et al.* 2018. Sci Rep. 13:e0199785. [PubMed](#)
24. Pereira JL, *et al.* 2021. Transl Oncol. 14:101125. [PubMed](#)
25. Zirngibl F, *et al.* 2021. J Immunother Cancer. 9:.. [PubMed](#)
26. Wilson AS, *et al.* 2022. Nat Commun. 13:528. [PubMed](#)
27. Mandrup OA, *et al.* 2021. Commun Biol. 310:4. [PubMed](#)
28. Burrack K, *et al.* 2015. PLoS Pathog. 11: e1005191. [PubMed](#)
29. Brummer G, *et al.* 2020. Oncogene. 39:2275. [PubMed](#)
30. Leonard JD *et al.* 2017. Immunity. 47(1):107-117 . [PubMed](#)
31. Park D, *et al.* 2020. Cancer Res. 80:4172. [PubMed](#)
32. Uhde A, *et al.* 2016. PLoS One. 11: 0161883. [PubMed](#)
33. Dietmar Herndler-Brandstetter *et al.* 2018. Immunity. 48(4):716-729 . [PubMed](#)
34. Fontinha D, *et al.* 2015. PLoS One. 10: 0142540. [PubMed](#)
35. Baier FA, *et al.* 2021. Cell Mol Gastroenterol Hepatol. 12:745. [PubMed](#)
36. Stanford S, *et al.* 2012. Proc Natl Acad Sci U S A. 109:13972. [PubMed](#)
37. Haile S, *et al.* 2014. Cancer Immunol Res. 2:610. [PubMed](#)
38. White C, *et al.* 2015. J Immunol. 194:697. [PubMed](#)
39. Uddback I, *et al.* 2016. Sci Rep. 6:20137. [PubMed](#)
40. Li C, *et al.* 2020. Immunity. 52(1):201-202. [PubMed](#)
41. Shen M, *et al.* 2022. Nat Cancer. 3:60. [PubMed](#)
42. Yan J, *et al.* 2020. Cell Rep. 107820:31. [PubMed](#)
43. Lim S, *et al.* 2016. PLoS One. 11: 0155689. [PubMed](#)
44. XS R, *et al.* 2015. Diabetes. 64 90. [PubMed](#)
45. Moore MJ *et al.* 2018. eLife. 7 pii: e33057. [PubMed](#)
46. Kang X, *et al.* 2022. J Immunol Res. 2022:8118577. [PubMed](#)
47. Rashid MH, *et al.* 2021. Oncol Rep. 45:1171. [PubMed](#)
48. Tao F, *et al.* 2013. Biochem Pharmacol. 85:798. [PubMed](#)
49. Zhang W, *et al.* 2019. Mar Drugs. 0.845138889. [PubMed](#)
50. Kretschmer L, *et al.* 2020. Nat Commun. 0.536805556. [PubMed](#)
51. Ma K, *et al.* 2022. iScience. 25:104347. [PubMed](#)
52. Riva A, *et al.* 2017. PLoS One.. 10.1371/journal.pone.0181964. [PubMed](#)
53. Martina M, *et al.* 2016. J Am Soc Nephrol. 27: 1113-1123. [PubMed](#)
54. Wang L, *et al.* 2021. Sci Adv. 7:eabj4796. [PubMed](#)
55. Jing Y, *et al.* 2021. Front Immunol. 12:651860. [PubMed](#)
56. Niven J, *et al.* 2019. Cell Rep. 28:21. [PubMed](#)
57. Kiss M, *et al.* 2020. Cancer Immunol Res. 9:309. [PubMed](#)
58. Bommarreddy PK, *et al.* 2019. J Biol Methods. 6:2. [PubMed](#)
59. Tsyklauri O, *et al.* 2021. EMBO Rep. 22:e50785. [PubMed](#)
60. Rui J, *et al.* 2021. Nat Commun. 12:5074. [PubMed](#)
61. Song TY, *et al.* 2021. Nat Commun. 12:7003. [PubMed](#)
62. Klezovich-Bénard M, *et al.* 2012. PLoS One. 8:e1002481. [PubMed](#)
63. Skirecki T, *et al.* 2020. JCI Insight. 5:.. [PubMed](#)
64. Wang N, *et al.* 2020. Front Immunol. 1.765972222. [PubMed](#)
65. Gardner A, *et al.* 2022. J Immunother Cancer. 10:.. [PubMed](#)
66. Zhang M, *et al.* 2022. iScience. 25:104490. [PubMed](#)
67. Han J, *et al.* 2015. Cancer Res . 75: 5273 - 5282. [PubMed](#)
68. Kuhn NF *et al.* 2019. Cancer cell. 35(3):473-488 . [PubMed](#)
69. Li X, *et al.* 2021. Front Cell Dev Biol. 9:647713. [PubMed](#)

## RRID

AB\_313108 (BioLegend Cat. No. 104505)  
AB\_313109 (BioLegend Cat. No. 104506)

## Antigen Details

---

### Structure

C-type lectin, 27/33 kD

<b>Distribution</b>	Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets
<b>Function</b>	Lymphocyte activation
<b>Cell Type</b>	B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
<b>Biology Area</b>	Costimulatory Molecules, Immunology, Innate Immunity
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay AN, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Testi R, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:479.</li> <li>3. Moretta A, <i>et al.</i> 1991. <i>J. Exp. Med.</i> 174:1393.</li> <li>4. Yokoyama WM, <i>et al.</i> 1988. <i>J. Immunol.</i> 141:369.</li> </ol>
<b>Gene ID</b>	<a href="#">12515</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Biotin anti-mouse CD69, FITC anti-mouse CD69, PE anti-mouse CD69, PE/Cyanine5 anti-mouse CD69, Purified anti-mouse CD69, PE/Cyanine7 anti-mouse CD69, APC anti-mouse CD69, Alexa Fluor® 488 anti-mouse CD69, Alexa Fluor® 647 anti-mouse CD69, PerCP anti-mouse CD69, PerCP/Cyanine5.5 anti-mouse CD69, Pacific Blue™ anti-mouse CD69, Brilliant Violet 421™ anti-mouse CD69, APC/Cyanine7 anti-mouse CD69, Brilliant Violet 605™ anti-mouse CD69, Brilliant Violet 510™ anti-mouse CD69, Purified anti-mouse CD69 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD69, Brilliant Violet 711™ anti-mouse CD69, Alexa Fluor® 700 anti-mouse CD69, Brilliant Violet 650™ anti-mouse CD69, Brilliant Violet 785™ anti-mouse CD69, TotalSeq™-A0197 anti-mouse CD69, APC/Fire™ 750 anti-mouse CD69, TotalSeq™-C0197 anti-mouse CD69, TotalSeq™-B0197 anti-mouse CD69, KIRAVIA Blue 520™ anti-mouse CD69, Spark NIR™ 685 anti-mouse CD69, Spark Red™ 718 anti-mouse CD69

## Product Data



PMA-stimulated (6 hours) splenocytes stained with H1.2F3 FITC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587